Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Kidney Neoplasms 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Pheochromocytoma 1Paraganglioma 1Neoplasms, Germ Cell and Embryonal 1Gastrointestinal Stromal Tumors 1Carcinoma, Transitional Cell 1

Interventions

Cyclophosphamide 4Etoposide 3pembrolizumab 2fludarabine 2etoposide phosphate 2Sirolimus 2Paclitaxel 2Mesna 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Cisplatin 2Carboplatin 2Busulfan 2Brentuximab Vedotin 2tremelimumab 1ripretinib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1pazopanib 1guadecitabine 1fosaprepitant 1fludarabine phosphate 1durvalumab 1bintrafusp alfa protein, human 1avelumab 1Vorinostat 1Ursodeoxycholic Acid 1Topotecan 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Germ Cell and Embryonal × guadecitabine × Genitourinary × Clear all
NCT02429466 2020-09-23

Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors

Indiana University

Phase 1 Completed
14 enrolled
Genitourinary

Testicular Germ Cell Tumor, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡